Threshold of 6 mm on Retropharyngeal Lymph Node Predicts PFS in Nasopharyngeal Carcinoma
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Oct. 2, 2023 -- For patients with nasopharyngeal carcinoma (NPC), a minimal axial diameter (MAD) threshold of 6 mm for retropharyngeal lymph node (RLN) predicts survival, according to a study published online Sept. 27 in the American Journal of Roentgenology.
Yuliang Zhu, Ph.D., from Zhongshan City People's Hospital in China, and colleagues investigated the optimal size thresholds for determining the presence of metastatic RLNs on magnetic resonance imaging (MRI) in a retrospective study involving 1,752 patients with NPC treated by intensity-modulated radiotherapy from January 2010 to March 2014. A total of 438 patients underwent MRI three to four months after treatment.
The researchers found that an optimal threshold of 6 mm was detected on receiver operating curve and restricted cubic spline analyses. MAD ≥6 mm independently predicted progression-free survival (PFS) in all patients, patients with N0 to N1 disease, and those who underwent posttreatment MRI in multivariable analyses (hazard ratios, 1.35, 1.80, and 1.68, respectively). Five-year PFS was worse for MAD ≥6 mm than for MAD ≥5 to <6 mm in patients with N1 disease without cervical lymph node involvement (77.2 versus 89.7 percent). For patients with stage I and stage II disease defined using a 6-mm -- but not using a 5-mm -- threshold, overall survival was significantly different. The rate of five-year PFS was associated with postradiation therapy MAD ≥6 mm, but not ≥5 mm (hazard ratio, 1.68).
"Given the absence of a defined size threshold in the American Joint Committee on Cancer 8th edition staging manual, we propose that future updates to the manual incorporate this threshold for N-category and tumor-stage determination," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.